Form 4: PTC Therapeutics EVP Sells Shares for Tax Obligations

PTC Therapeutics' EVP & Chief Medical Officer, Lee Scott Golden, sold 866 shares of common stock at $76.45 per share to cover tax withholding obligations related to RSU vesting.

Summary

• Lee Scott Golden, Executive Vice President and Chief Medical Officer of PTC Therapeutics, Inc. (PTCT), reported a transaction involving the company's common stock.
• The transaction, executed on January 8, 2026, was a sale of 866 shares of common stock.
• The shares were sold at a price of $76.45 per share.
• This sale was an automatic 'sell to cover' transaction, pre-arranged under a Rule 10b5-1 plan, to satisfy tax withholding obligations.
• The tax obligations arose from the vesting of 3,539 Restricted Stock Units (RSUs), which were part of a larger grant of 14,155 RSUs made on January 7, 2022.
• Following this transaction, Golden beneficially owns 92,428 shares of PTC Therapeutics common stock.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine 'sell to cover' for tax purposes, not indicative of management's sentiment towards the company's future performance. It's a standard part of executive compensation.

Positives

• The transaction was a 'sell to cover' for tax obligations, indicating it was not a discretionary sale based on a negative outlook for the company.
• The sale was pre-planned under a Rule 10b5-1 contract, which suggests a structured and non-opportunistic approach to insider transactions.

Negatives

• A minor reduction in direct insider ownership, although for a routine tax-related purpose.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction for tax purposes, a common occurrence across all industries for executives who receive equity compensation. It does not provide specific insights into broader industry trends or competitive dynamics.

Comparison to Industry Standards

• This transaction is a standard 'sell to cover' for tax purposes, a common practice for executives across publicly traded companies when equity awards like Restricted Stock Units (RSUs) vest.
• The use of a Rule 10b5-1 plan for such a transaction is also a widely adopted corporate governance practice to mitigate concerns about opportunistic insider trading.

Related Party Transactions

• The reported transaction is a related party transaction involving an executive officer selling company shares.

Stakeholder Impact

• Shareholders: The transaction represents a minor reduction in insider ownership, but as a routine tax-related sale, it is unlikely to significantly impact shareholder confidence or the company's valuation.
• Employees, Customers, Suppliers, Creditors: No direct impact is expected from this routine insider transaction.

Key Dates

Recommendation

This Form 4 filing details a routine 'sell to cover' transaction by an executive to satisfy tax obligations upon RSU vesting, pre-arranged under a Rule 10b5-1 plan. Such transactions are common and do not typically reflect management's discretionary view on the company's future prospects. Therefore, this filing alone provides insufficient information to alter an investment thesis, warranting a 'hold' recommendation as it does not present new fundamental insights for a seasoned investor.

Keywords

PTC Therapeutics, PTCT, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Lee Scott Golden, Executive Compensation, Rule 10b5-1